Sigmovir Biosystems

Sigmovir Biosystems

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $17.5M

Overview

Sigmovir Biosystems is a specialized contract research organization (CRO) and animal model provider focused exclusively on the cotton rat model for infectious diseases. Founded in 2015, the company capitalizes on over 100 years of combined team experience with this model, which is considered superior to standard mice for many respiratory and other viral infections like RSV, influenza, and HSV. Its business revolves around providing fee-for-service research, developing proprietary reagents, and supplying animals to academic and commercial clients, positioning it as a niche expert in preclinical infectious disease research. The company's work has directly supported the advancement of clinical candidates, most notably prophylactic antibodies for RSV.

Infectious Disease

Technology Platform

Specialized cotton rat (Sigmodon species) animal model for preclinical research on human infectious diseases, supported by a proprietary toolkit of species-specific reagents and deep genetic/immunological expertise.

Funding History

2
Total raised:$17.5M
Series A$15M
Seed$2.5M

Opportunities

Growing investment in infectious disease R&D, particularly for RSV, influenza, and emerging viruses, drives demand for predictive preclinical models.
The proven translational success of the cotton rat model for key pathogens positions SBI as a preferred partner for de-risking clinical candidates.
Expansion of the model into new disease areas (bacterial, parasitic) and continued reagent development offer avenues for market growth.

Risk Factors

High dependence on the continued scientific and commercial adoption of a single, non-standard animal model creates concentration risk.
Revenue may be volatile and project-dependent, subject to the R&D cycles of biopharma clients.
Operational risks include maintaining a specialized animal colony and potential regulatory changes in animal research standards.

Competitive Landscape

SBI competes within the broader preclinical CRO market and specifically in the niche of specialized animal models. Direct competitors include other CROs offering cotton rat services (e.g., certain university-affiliated facilities) and providers of alternative models like ferrets, hamsters, or humanized mice for infectious disease. Its competitive edge is its deep, focused expertise, proprietary reagents, and established reputation as the leading authority on the cotton rat model.